SpringerLink
Log in

Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Objective: To investigate the prevalence of cardiovascular risk factors in patients with primary hyperparathyroidism (PHPT) and to determine if they are gender specific. Methods: This was a retrospective case control study. Three hundred and sixty-three men and women with PHPT and 363 age-, sex-, and body mass index (BMI)-matched controls with benign goiter were included in the study. We documented each patient’s laboratory results along with the presence of any cardiovascular risk factors. Intra-operatively, the resected parathyroid adenomas were weighed and recorded. The data are expressed as the number of patients in each category and percentage of total patients in that group and the mean±SD. Results: The prevalence of obesity, hypertension, hyperlipidemia, Type 2 diabetes, and coronary artery disease (CAD) is higher in PHPT patients compared to the general New Jersey population and age-, sex-, and BMI-matched goiter patients. Male PHPT patients tended to be more obese and were found to have heavier parathyroid adenomas compared to female patients (p<0.05). Additionally, a higher percentage of male PHPT patients were found to have higher rates of CAD (11.5%) and Type 2 diabetes (23.0%) compared to female patients (5.80% and 10.9%, respectively, p<0.05). Conclusions: There is a higher prevalence of metabolic disorders and CAD in PHPT patients. Male PHPT patients had larger parathyroid adenomas at the time of surgery and had a higher prevalence of obesity, Type 2 diabetes and CAD compared to female PHPT patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006, 1: 171–7.

    Google Scholar 

  2. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 2004, 350: 1746–51.

    Article  PubMed  Google Scholar 

  3. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism: 10-year prospective study. Mayo Clin Proc 1981, 56: 473–8.

    PubMed  Google Scholar 

  4. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999, 341: 1249–55.

    Article  PubMed  Google Scholar 

  5. Potts JT, Franklin JE, Aurbach GD, et al. Proceedings of the NIH consensus development conference on diagnosis and management of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991, 6(Suppl 2): S1–166.

    Google Scholar 

  6. Bilezikian JP, Potts JT, El-Hajj Fuleihan G, et al. Summary statement from a workshop on asymptomatic hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002, 87: 353–61.

    Google Scholar 

  7. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008, 93: 3462–70.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988, 67: 1294–8.

    Article  PubMed  Google Scholar 

  9. Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 1996, 81: 3487–91.

    PubMed  Google Scholar 

  10. Bolland MJ, Grey AB, Ames RW, Horne AM, Gamble GD, Reid IR. Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone 2006, 38: 317–21.

    Article  PubMed  Google Scholar 

  11. Siilin H, Rastad J, Ljunggren O, Lundgren E. Disturbances of calcium homeostasis consistent with mild primary hyperparathyroidism in premenopausal women and associated morbidity. J Clin Endocrinol Metab 2008, 93: 47–53.

    Article  PubMed  Google Scholar 

  12. Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a metaanalysis. J Clin Endocrinol Metab 2005, 90: 1525–30.

    Article  PubMed  Google Scholar 

  13. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone level is associated with body mass index. The 5th Tromsø study. Eur J Endocrinol 2004, 151: 167–72.

    Article  PubMed  Google Scholar 

  14. Ayturk S, Gursoy A, Bascil Tutuncu N, Ertugrul DT, Guvener Demirag N. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2006, 91: 4260–3.

    Article  PubMed  Google Scholar 

  15. Shaw JT, Purdie DM, Neil HA, Levy JC, Turner RC. The relative risks of hyperglycaemia, obesity and dyslipidaemia in the relatives of patients with type II diabetes mellitus. Diabetologia 1999, 42: 24–7.

    Article  PubMed  Google Scholar 

  16. Procopio M, Magro G, Cesario F, et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 Diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002, 19: 958–61.

    Article  PubMed  Google Scholar 

  17. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe: nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002, 17(Suppl 2): N68–74.

    PubMed  Google Scholar 

  18. Cardenas MG, Vigil KJ, Talpos GB, Lee MW, Peterson E, Rao DS. Prevalence of type 2 Diabetes mellitus in patients with primary hyperparathyroidism. Endocr Pract 2008, 14: 69–75.

    Article  PubMed  Google Scholar 

  19. Wermers RA, Khosla S, Atkinson EJ, et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998, 104: 115–22.

    Article  PubMed  Google Scholar 

  20. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. www.OpenEpi.com, updated 2010/19/09, accessed 2011/04/02.

  21. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88: 1174–8.

    Article  PubMed  Google Scholar 

  22. Marcus R. The role of estrogens and related compounds in the management of primary hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl 2): N146–9.

    PubMed  Google Scholar 

  23. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem 2007, 282: 3098–106.

    Google Scholar 

  24. Sukumar D, Partridge NC, Wang X, Shapses SA. The high serum monocyte chemoattractant protein-1 in obesity is influenced by high parathyroid hormone and not adiposity. J Clin Endocrinol Metab 2011, 96: 1852–8.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Khan AA, Bilezikian JP, Potts JT Jr; Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab 2009, 94: 333–4.

    Article  PubMed  Google Scholar 

  26. Xu KT, Borders TF. Gender, health, and physician visits among adults in the United States. A J Pub Health 2003, 93: 1076–9.

    Article  Google Scholar 

  27. Adam MA, Untch BR, Danko ME, et al. Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J Clin Endocrinol Metab 2010, 95: 4917–24.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007, 92: 1687–92.

    Article  PubMed  Google Scholar 

  29. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007, 92: 3114–21.

    Article  PubMed  Google Scholar 

  30. Bollerslev J, Rosen T, Mollerup CL, et al; SIPH Study Group. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94: 2255–61.

    Article  PubMed  Google Scholar 

  31. Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003, 27: 216–22.

    Article  PubMed  Google Scholar 

  32. Vestergaard P, Mosekilde L. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 2003, 327: 530–4.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of General Surgery, Deparment of Surgery, New Brunswick, New Jersey, USA

    D. Han & S. Trooskin

  2. Division of Endocrinology, Departments of Medicine, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

    D. Han & X. Wang MD, PhD, FACE

Authors
  1. D. Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Trooskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X. Wang MD, PhD, FACE
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. Wang MD, PhD, FACE.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, D., Trooskin, S. & Wang, X. Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J Endocrinol Invest 35, 548–552 (2012). https://doi.org/10.3275/7861

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/7861

Key-words

Search

Navigation